Successful treatment with IVIg therapy of diabetes-associated scleredema severe progressive case and review of the literature

Pavlidakey, Peter; Sami, Naveed

doi:10.1111/dth.12504

Cited by 10 publications

(7 citation statements)

References 9 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are some cases describing intravenous immunoglobulin use. 5 , 6 Some case reports also describe treatment with radiotherapy and prostaglandin E1, 4, 5. 8 Other novel therapies have recently been suggested, such as tranilast.…”

Section: Discussionmentioning

confidence: 99%

Scleredema diabeticorum

Pereira¹,

Pinheiro²,

Lencastre³

et al. 2022

Dermatol Reports

View full text Add to dashboard Cite

Scleredema of Buschke is a rare connective tissue disease with a poorly understood pathogenesis. Three types of scleredema have been distinguished according to its association with preceding or underlying conditions. Type 1 is usually secondary to a febrile infection, type 2 is mostly associated with paraproteinemia and type 3, usually named scleredema diabeticorum, has a strict association with Diabetes mellitus. A diffuse, non-pitting swelling and induration of the skin define this disease. The skin histology is characterized by a normal or slightly thinned epidermis, and the dermis containing a decreased number of elastic fibers and thick large swollen collagen bundles separated by mucopolysaccharide deposits in the deep reticular dermis. In this report we present a 58-year-old man with scleredema diabeticorum controlled with a topical steroid cream and an optimization of glycemic control. We reviewed clinical, histopathological characteristics and the various possible treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Scleredema diabeticorum

Pereira¹,

Pinheiro²,

Lencastre³

et al. 2022

Dermatol Reports

View full text Add to dashboard Cite

show abstract

“…IVIG was used in the treatment of 10 patients with severe and resistant pyoderma gangrenosum who could not respond despite multidrug therapy, and improved in seven patients (Cummins, Anhalt, Monahan, & Meyerle, 2007). In treatment-resistant livedoid vasculopathy and scleredema, it has been reported that IVIG is fast effective and safe treatment option (Kennemer, Pavlidakey, & Sami, 2017;Yoshioka, Tateishi, Kato, & Chen, 2018). (Fernandez & Kerdel, 2007;Forbat et al, 2018;Smith, Dennington, & Cooper, 2010).…”

Section: Other Indicationsmentioning

confidence: 99%

Intravenous immunoglobulin treatment: Where do dermatologists stand?

Emre

2019

Dermatologic Therapy

View full text Add to dashboard Cite

Intravenous immunoglobulins (IVIG) are therapeutic products, comprising polyclonal IgGs, which are obtained from human plasma pool of healthy blood donors. Despite the lack of Food and Drug Administration (FDA) approval, the experience of using IVIG in various dermatological diseases increases day by day and exciting results are reported. However, experience with the use of IVIG in dermatological indications are mostly case reports whereas randomized, controlled, double‐blind, multicentric studies have not been performed. Dermatological diseases treated with IVIG are autoimmune bullous skin diseases, Stevens‐Johnson syndrome and toxic epidermal necrolysis, connective tissue diseases, pyoderma gangrenosum, severe atopic dermatitis, chronic urticaria, Kawasaki disease, pretibial myxoedema, scleredema, and graft‐versus‐host disease.

show abstract

“…To our knowledge, five previous reports described successful IVIG treatment in scleredema 3 4 5 . However, there were no reports of concurrent monoclonal gammopathy and type 1 DM associated scleredema.…”

mentioning

confidence: 94%

“…NB-UVB phototherapy may affect keratinocyte-fibroblast interaction to inhibit fibroblast activation 3 . IVIG has been reported with successful response in some cases 4 5 . It is suggested that it may reduce glycosaminoglycans in the skin by acting on the Fc receptor and regulating innate and adaptive immunity.…”

mentioning

confidence: 99%